| Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice J Fareed, D Hoppensteadt, J Walenga, O Iqbal, Q Ma, W Jeske, T Sheikh Clinical pharmacokinetics 42, 1043-1057, 2003 | 173 | 2003 |
| Pro-inflammatory biomakers in depression: treatment with venlafaxine JE Piletz, A Halaris, O Iqbal, D Hoppensteadt, J Fareed, H Zhu, J Sinacore, ... The World Journal of Biological Psychiatry 10 (4), 313-323, 2009 | 166 | 2009 |
| Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia JM Walenga, S Ahmad, D Hoppensteadt, O Iqbal, MJ Hursting, BE Lewis Thrombosis research 105 (5), 401-405, 2002 | 104 | 2002 |
| Rivaroxaban–an oral, direct Factor Xa inhibitor–has potential for the management of patients with heparin‐induced thrombocytopenia JM Walenga, M Prechel, WP Jeske, D Hoppensteadt, J Maddineni, ... British journal of haematology 143 (1), 92-99, 2008 | 103 | 2008 |
| Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor M Tobu, O Iqbal, D Fareed, M Chatha, D Hoppensteadt, V Bansal, ... Clinical and applied thrombosis/hemostasis 10 (3), 225-232, 2004 | 98 | 2004 |
| Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes J Fareed, DA Hoppensteadt, F Leya, O Iqbal, H Wolf, R Bick Clinical chemistry 44 (8), 1845-1853, 1998 | 92 | 1998 |
| Coagulation laboratory testing in patients treated with argatroban. JM Walenga, AR Fasanella, O Iqbal, DA Hoppensteadt, S Ahmad, ... Seminars in thrombosis and hemostasis 25, 61-66, 1999 | 80 | 1999 |
| Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88) M Demir, O Iqbal, DA Hoppensteadt, P Piccolo, S Ahmad, CL Schultz, ... Clinical and Applied Thrombosis/Hemostasis 7 (2), 131-140, 2001 | 66 | 2001 |
| An update on the pathogenesis of COVID-19 and the reportedly rare thrombotic events following vaccination B Kantarcioglu, O Iqbal, JM Walenga, B Lewis, J Lewis, CA Carter, ... Clinical and Applied Thrombosis/Hemostasis 27, 10760296211021498, 2021 | 57 | 2021 |
| Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins S Alban, R Gastpar Thrombosis and haemostasis 85 (05), 824-829, 2001 | 53 | 2001 |
| Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict all-cause mortality in acute pulmonary embolism T Phan, Y Brailovsky, J Fareed, D Hoppensteadt, O Iqbal, A Darki Clinical and Applied Thrombosis/Hemostasis 26, 1076029619900549, 2020 | 43 | 2020 |
| Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide C Adiguzel, O Iqbal, D Hoppensteadt, W Jeske, J Cunanan, E Litinas, ... Clinical and Applied Thrombosis/Hemostasis 15 (5), 501-511, 2009 | 43 | 2009 |
| Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis J Fareed, Q Ma, M Florian, J Maddineni, O Iqbal, DA Hoppensteadt, ... Seminars in thrombosis and hemostasis 30 (S 1), 89-104, 2004 | 41 | 2004 |
| The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model P Bacher, D Welzel, O Iqbal, D Hoppensteadt, D Callas, JM Walenga, ... Thrombosis research 66 (2-3), 151-158, 1992 | 38 | 1992 |
| Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma M Mohri, M Suzuki, E Sugimoto, M Sata, S Yamamoto, I Maruyama Thrombosis and haemostasis 80 (12), 925-929, 1998 | 34 | 1998 |
| Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide. DD Callas, DA Hoppensteadt, W Jeske, O Iqbal, P Bacher, A Ahsan, ... Seminars in thrombosis and hemostasis 19, 49-57, 1993 | 34 | 1993 |
| Stroke care trends during COVID-19 pandemic in Zanjan Province, Iran. from the cascade initiative: statistical analysis plan and preliminary results A Ghoreishi, S Arsang-Jang, Z Sabaa-Ayoun, N Yassi, PN Sylaja, ... Journal of Stroke and Cerebrovascular Diseases 29 (12), 105321, 2020 | 32 | 2020 |
| Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants M Tobu, O Iqbal, D Hoppensteadt, B Neville, HL Messmore, J Fareed Clinical and applied thrombosis/hemostasis 10 (4), 301-309, 2004 | 32 | 2004 |
| European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats C Adiguzel, O Iqbal, M Demir, J Fareed Clinical and Applied Thrombosis/Hemostasis 15 (6), 645-651, 2009 | 31 | 2009 |
| Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values F Siddiqui, A Tafur, LS Ramacciotti, W Jeske, D Hoppensteadt, ... Clinical and Applied Thrombosis/Hemostasis 25, 1076029619863493, 2019 | 29 | 2019 |
